Spero Therapeutics and partner GSK are stopping a late-stage trial of an experimental oral drug for complicated urinary tract ...

Patterson-UTI Energy, Inc. ( NASDAQ:PTEN ) will pay a dividend of $0.08 on the 16th of June. The dividend yield will ...

Watford MP Matt Turmaine emphasised the urgent need for a cure for chronic urinary tract infections (UTIs) at Parliament last ...

USA: A recent large-scale retrospective study published in the European Journal of Obstetrics & Gynecology and Reproductive ...

GSK and Spero Therapeutics’ Phase III trial of their oral antibiotic for complicated urinary tract infections (cUTI) will end ...

Spero Therapeutics (SPRO) stock jumps as GSK (GSK) partnered oral UTI treatment, tebipenem HBr, succeeds in a pivotal Phase 3 ...

The category's average allocation to large, mid, and smallcaps was 48.09 per cent, 12.63 per cent and 9.34 per cent, ...

A common over-the-counter drug used by millions to relieve UTI symptoms is now under serious scrutiny. Phenazopyridine — sold under brand names like Azo and Pyridium — has been linked to cancer in ...

GSK’s decision to swoop in and save Spero Therapeutics’ antibiotic three years ago appears to have paid off based on a fresh ...

GSK and Spero Therapeutics announced that a Phase 3 trial for their complicated UTI antibiotic reached its primary endpoint, ...

UTIs are among the most common infections worldwide, affecting some 15 million women a year. Phenazopyridine, sold under brand names such as Azo and Uristat, is used to treat the pain, burning and ...

V Srivatsa and Sunil Madhukar Patil have been managing this fund since November 2009 and February 2018, respectively ...